Inflammasome activation and vitiligo/nonsegmental vitiligo progression

British Journal of Dermatology

Volumn 170, Issue 4, 2014, Pages 816-823

  Marie, J ^a   Kovacs, D ^b   Pain, C ^a,c,d   Jouary, T ^a   Cota, C ^b   Vergier, B ^e   Picardo, M ^b   Taieb, A ^a,c,d   Ezzedine, K ^a,c,d   Cario Andre M ^a,c,d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSERM U1035 Biothérapie des Maladies Génétiques et Cancers ^*  (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1BETA; NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT 1; NUCLEOTIDE BINDING PROTEIN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BIOLOGICAL MARKER; KALLIKREIN; NLRP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; NONSEGMENTAL VITILIGO; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; T LYMPHOCYTE; VITILIGO; ADOLESCENT; AGED; CASE CONTROL STUDY; LYMPHOCYTE; METABOLISM; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMASOMES; INTERLEUKIN-1BETA; KALLIKREINS; LYMPHOCYTES; MALE; MIDDLE AGED; VITILIGO;

EID: 84921901906     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12691     Document Type: Article

References (24)

1. Taïeb A, Picardo M,. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
2. Ezzedine K, Lim HW, Suzuki T, et al,. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25: E1-13.
3. Picardo M, Taïeb A,. Vitiligo. Berlin, Heidelberg: Springer, 2010.
4. Ezzedine K, Diallo A, Léauté-Labrèze C, et al,. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol 2011; 165: 44-9.
5. Badri AM, Todd PM, Garioch JJ, et al,. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993; 170: 149-55.
6. Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al,. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80: 1299-309.
7. Lili Y, Yi W, Ji Y, et al,. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012; 7: e37513.
8. Jin Y, Mailloux CM, Gowan K, et al,. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356: 1216-25.
9. Alkhateeb A, Jarun Y, Tashtoush R,. Polymorphisms in NLRP1 gene and susceptibility to autoimmune thyroid disease. Autoimmunity 2013; 46: 215-21.
10. Magitta NF, Bøe Wolff AS, Johansson S, et al,. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun 2009; 10: 120-4.
11. Levandowski CB, Mailloux CM, Ferrara TM, et al,. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA 2013; 110: 2952-6.
12. Deo S, Bhagat A, Shah R,. Genetic variations in NALP1 mRNA expressions in human vitiligo. Indian J Dermatol 2011; 56: 266-71.
13. Dwivedi M, Laddha NC, Mansuri MS, et al,. Association of NALP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in Gujarat population. Br J Dermatol 2013; 169: 1114-25.
14. Kummer JA, Broekhuizen R, Everett H, et al,. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007; 55: 443-52.
15. Feldmeyer L, Keller M, Niklaus G, et al,. The inflammasome mediates UVB-induced activation and secretion of interleukin-1β by keratinocytes. Curr Biol 2007; 17: 1140-5.
16. Lundqvist EN, Egelrud T,. Biologically active, alternatively processed interleukin-1 beta in psoriatic scales. Eur J Immunol 1997; 27: 2165-71.
17. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, et al,. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011; 6: e18907.
18. Kroll TM, Bommiasamy H, Boissy RE, et al,. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 2005; 124: 798-806.
19. Taïeb A,. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res 2012; 25: 9-13.
20. Naughton GK, Eisinger M, Bystryn JC,. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81: 540-2.
21. Harning R, Cui J, Bystryn JC,. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-80.
22. Naughton GK, Reggiardo D, Bystryn JC,. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-81.
23. Pétrilli V, Dostert C, Muruve DA, et al,. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-22.
24. Taïeb A,. NALP1 and the inflammasomes: challenging our perception of vitiligo and vitiligo-related autoimmune disorders. Pigment Cell Res 2007; 20: 260-2.